-
1
-
-
77956301345
-
Combretastatin A4 phosphate: A novel vascular disrupting agent
-
Nagaiah G, Remick SC. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol 2010; 6: 1219-1228.
-
(2010)
Future Oncol
, vol.6
, pp. 1219-1228
-
-
Nagaiah, G.1
Remick, S.C.2
-
2
-
-
0036959614
-
Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors
-
Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002; 12: 1063-1070. (Pubitemid 36114813)
-
(2002)
Thyroid
, vol.12
, Issue.12
, pp. 1063-1070
-
-
Dziba, J.M.1
Marcinek, R.2
Venkataraman, G.3
Robinson, J.A.4
Ain, K.B.5
-
3
-
-
0035129337
-
Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: Preclinical efficacy
-
DOI 10.1097/00001813-200101000-00008
-
Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, et al. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 2001; 12: 57-63. (Pubitemid 32142284)
-
(2001)
Anti-Cancer Drugs
, vol.12
, Issue.1
, pp. 57-63
-
-
Nabha, S.M.1
Mohammad, R.M.2
Wall, N.R.3
Dutcher, J.A.4
Salkini, B.M.5
Pettit, G.R.6
Al-Katib, A.M.7
-
4
-
-
0042887593
-
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate
-
DOI 10.1200/JCO.2003.05.186
-
Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21: 2823-2830. (Pubitemid 46621829)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.15
, pp. 2823-2830
-
-
Anderson, H.L.1
Yap, J.T.2
Miller, M.P.3
Robbins, A.4
Jones, T.5
Price, P.M.6
-
5
-
-
0642307227
-
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow
-
DOI 10.1200/JCO.2003.12.986
-
Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5- day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-4438. (Pubitemid 46621821)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.23
, pp. 4428-4438
-
-
Stevenson, J.P.1
Rosen, M.2
Sun, W.3
Gallagher, M.4
Haller, D.G.5
Vaughn, D.6
Giantonio, B.7
Zimmer, R.8
Petros, W.P.9
Stratford, M.10
Chaplin, D.11
Young, S.L.12
Schnall, M.13
O'Dwyer, P.J.14
-
6
-
-
1642494772
-
Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer
-
DOI 10.1158/1078-0432.CCR-0364-3
-
Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004; 10: 96-100. (Pubitemid 38114167)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.1
, pp. 96-100
-
-
Cooney, M.M.1
Radivoyevitch, T.2
Dowlati, A.3
Overmoyer, B.4
Levitan, N.5
Robertson, K.6
Levine, S.L.7
DeCaro, K.8
Buchter, C.9
Taylor, A.10
Stambler, B.S.11
Remick, S.C.12
-
7
-
-
20044395276
-
Phase I trial of combretastatin A-4 phosphate with carboplatin
-
DOI 10.1158/1078-0432.CCR-04-1434
-
Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005; 11: 1527-1533. (Pubitemid 40315236)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.4
, pp. 1527-1533
-
-
Bilenker, J.H.1
Flaherty, K.T.2
Rosen, M.3
Davis, L.4
Gallagher, M.5
Stevenson, J.P.6
Sun, W.7
Vaughn, D.8
Giantonio, B.9
Zimmer, R.10
Schnall, M.11
O'Dwyer, P.J.12
-
8
-
-
84862532904
-
Phase i trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer
-
Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 2012; 18: 3428-3439.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3428-3439
-
-
Nathan, P.1
Zweifel, M.2
Padhani, A.R.3
Koh, D.M.4
Ng, M.5
Collins, D.J.6
-
9
-
-
77951667223
-
A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
-
Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS,Wang D, et al. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102: 1355-1360.
-
(2010)
Br J Cancer
, vol.102
, pp. 1355-1360
-
-
Rustin, G.J.1
Shreeves, G.2
Nathan, P.D.3
Gaya, A.4
Ganesan, T.S.5
Wang, D.6
-
10
-
-
80053970544
-
A report from the 47th Annual Meeting of the American Society of Clinical Oncology
-
June 3-7
-
Rabasseda X, Gomez-Zaera M. A report from the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois, USA: Drugs of today; June 3-7, 2011; 47: 693-737.
-
(2011)
Chicago Illinois USA: Drugs of Today
, vol.47
, pp. 693-737
-
-
Rabasseda, X.1
Gomez-Zaera, M.2
-
11
-
-
79953648492
-
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
-
Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22: 2036-2041.
-
(2011)
Ann Oncol
, vol.22
, pp. 2036-2041
-
-
Zweifel, M.1
Jayson, G.C.2
Reed, N.S.3
Osborne, R.4
Hassan, B.5
Ledermann, J.6
-
12
-
-
12344312699
-
-
Cancer Therapy Evaluation Program., DCTD, NCI, NIH, DHHS;
-
Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, DCTD, NCI, NIH, DHHS; 2006.
-
(2006)
Common Terminology Criteria for Adverse Events
-
-
-
13
-
-
79952621559
-
Combretastatin-induced hypertension and the consequences for its combination with other therapies
-
Busk M, Bohn AB, Skals M,Wang T, Horsman MR. Combretastatin-induced hypertension and the consequences for its combination with other therapies. Vascul Pharmacol 2011; 54: 13-17.
-
(2011)
Vascul Pharmacol
, vol.54
, pp. 13-17
-
-
Busk, M.1
Bohn, A.B.2
Skals, M.3
Wang, T.4
Horsman, M.R.5
-
14
-
-
79955804161
-
A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours
-
He X, Li S, Huang H, Li Z, Chen L, Ye S, et al. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol 2011; 71: 860-870.
-
(2011)
Br J Clin Pharmacol
, vol.71
, pp. 860-870
-
-
He, X.1
Li, S.2
Huang, H.3
Li, Z.4
Chen, L.5
Ye, S.6
|